Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2a, open-label study to assess the effects of AK002


Clinical Trial Description

This open-label study is to assess the effects of AK002, given as monthly intravenous infusions at up to 3 mg/kg. A total of 47 patients will be enrolled across 2-4 sites. All patients enrolled in the study will receive 6 monthly infusions of AK002 and will then be followed for another 8 weeks. Some patients will have the option to receive an additional 12 months of extended dosing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03436797
Study type Interventional
Source Allakos Inc.
Contact
Status Completed
Phase Phase 2
Start date January 23, 2018
Completion date April 6, 2020

See also
  Status Clinical Trial Phase
Completed NCT02435238 - AWARE - Chronic Urticaria N/A
Not yet recruiting NCT05513079 - Positive Psychotherapy-Based Counseling (PPT) N/A
Terminated NCT02047136 - Dietary Treatment for Chronic Urticaria N/A
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Terminated NCT01170949 - Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria Phase 2
Completed NCT00598611 - Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Phase 3
Completed NCT01610128 - Development of an Urticaria Control Test N/A
Completed NCT02285023 - The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Completed NCT02285049 - Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test N/A
Completed NCT01715740 - Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria Phase 3
Completed NCT01960283 - Methotrexate in the Treatment of Chronic Idiopathic Urticaria Phase 3
Completed NCT00481676 - Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria Phase 2
Completed NCT01713725 - Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria Phase 2
Completed NCT01250652 - Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Phase 4
Completed NCT01111136 - Stress Intervention for Chronic Urticaria N/A
Recruiting NCT01425593 - T Cell Function in Chronic Idiopathic Urticaria N/A
Completed NCT00737451 - Association of Thyroid Autoimmunity and Chronic Urticaria N/A
Completed NCT00628108 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months Phase 3
Completed NCT00619801 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Phase 3
Completed NCT01284426 - Natural History of Chronic Urticaria N/A